Summary
In order to evaluate the neuroprotective effect of Rosiglitazone Maleate (RSG) against brain ischemic injury, the effects of Rosiglitazone Maleate on the inflammation following cerebral ischemia/reperfusion were investigated. Focal cerebral ischemia was induced by the intraluminal thread for cerebral middle artery (MCA) occlusion. Rosiglitazone Maleate at concentrations of 0.5, 2 and 5 mg/kg was infused by intragastric gavage twice immediately and 2 h after MCA occlusion, respectively. The effects of Rosiglitazone Maleate on brain swelling, myeloperoxidase and interleukin-6 mRNA level in brain tissue after MCA occlusion and reperfusion were evaluated. The results showed that as compared with the model control group, RSG (0.5 mg/kg) had no significant influence on brain swelling (P>0.05), but 2 mg/kg and 5 mg/kg RSG could significantly alleviate brain swelling (P<0.05). All different doses of RSG could obviously reduce MPO activity in brain tissue after MCA occlusion and reperfusion in a dose-dependent manner. RSG (0.5 and 2 mg/kg) could decrease the expression levels of IL-6 mRNA in brain tissue after MCA occlusion and reperfusion to varying degrees (P<0.05) with the difference being significant between them. It was concluded that RSG could effectively ameliorate brain ischemic injury after 24 h MCA occlusion and inhibit the inflammatory response after ischemia-reperfusion in this model.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Campbell I W. The clinical significance of PPAR gamma agonism. Curr Mol Med, 2005,5(3):349–363
Ito K, Shimada J, Kato D et al. Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats. Eur J Cadiothorac Surg, 2004,25(4):530–536
Ito H, Nakano A, Kinoshita M et al. Pioglitazone, a peroxisome oxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injuy in a rat model. Lab Invest, 2003,83(12):1715–1721
Abdelrahman M, Sivarajah A, Thiemermann C. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock, Cardiovasc Res, 2005,65(4):772–781
Becker K J. Inflammation and acute stroke. Curr Opin Neurol, 1998,11(1):45–49
Ritrer L, Coull B, Davisgoman G et al. Leukocytes accumulate in the cerebral microcirculation during the first hour of reperfusion following stroke. FASEB J, 1998,12:188–196
Ialenti A, Grassia G, Di Meglio P et al. Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway. Mol Pharmacol, 2005,67(5):1620–1628
Artwohl M, Holzenbein T, Furnsinn C et al. Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells. Thromb Haemost, 2005,93(5):810–815
Pistrosch F, Herbrig K, Oelschlaegel U et al. PPAR gamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis, 2005,183(1):163–167
Game B A, Maldonado A, He L et al. Pioglitazone inhibits MMP-1 expression in vascular smooth muscle cells through a mitogen-activated protein kinase-independent mechanism. Atherosclerosis, 2005,178(2):249–256
Author information
Authors and Affiliations
Additional information
XIONG Nanxiang, Male, born in 1973, Doctor in Charge
Rights and permissions
About this article
Cite this article
Xiong, N., Sun, F., Zhao, H. et al. Effect of Rosiglitazone Maleate on inflammation following cerebral ischemia/reperfusion in rats. J. Huazhong Univ. Sc. Technol. 27, 295–298 (2007). https://doi.org/10.1007/s11596-007-0320-x
Received:
Issue Date:
DOI: https://doi.org/10.1007/s11596-007-0320-x